Michel Vounatsos (Credit: World Economic Forum/Valeriano Di Domenico)
Under the gun with Aduhelm floundering, Biogen sells its stake in biosimilars business for $2.3B
It turns out the Korea Economic Daily was onto something when, over the Christmas break, it reported that Samsung was in the process of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
